24-hour efficacy for Crystawash Extend Hand Sanitiser

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 11 January 2021

AFT confirms demonstration of 24-hour efficacy for
Crystawash Extend Hand Sanitiser
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories
have found that its new Crystawash Extend Hand Sanitiser:
• Displays 24-hour residual efficacy against germs evidenced by testing on
synthetic skin
1
against S.Aureus and E.Coli
2

• Kills 99.99% of germs on immediate contact being S.Aureus, E.Coli,
P.aeruginosa, and E. hirae
3

• Meets the accepted standard for killing Corona virus, evidenced by activity
against the Corona virus surrogate [Murine hepatitis virus (MHV1)
4

The newly developed, ethanol free, foaming formulation adds to AFT’s existing
Crystawash sanitiser range in Australia and New Zealand and meets the huge
demand for hand sanitiser that has emerged with the Covid-19 pandemic. It also
enhances the appeal of AFT’s over-the-counter portfolio of medicines, now sold in
more than 6,000 pharmacies and other outlets across Australasia.
AFT Managing Director Dr Hartley Atkinson said: “Crystawash Extend’s long-lasting
protection offers real advantages over many other sanitisers, which are challenged
every time a new surface is touched.
“Crystawash Extend covers the hands with an invisible, water-proof, biostatic layer
that ruptures the membranes of germs upon contact. The result is effective hand
sanitisation and protection against contact of multiple germ-infected surfaces. The
chosen formulation was developed after rigorous testing on a number of potential
formulations”
Dr Atkinson said AFT believes the product has long-term potential.
“Despite the very welcome advent of several COVID-19 vaccines, we see no let-up in
demand for effective hand sanitiser. The vaccination programme will take some time
to roll out. And even after the programme has been completed, we expect consumer
interest in hand sanitisation to remain strong.”

Dr Atkinson said Crystawash Extend sales will add to this financial year’s results in
Australia and New Zealand and also has potential around the world as AFT leverages
its global network of partners to out-license the product in other jurisdictions. Already
Canada’s CombomedPharma Inc has agreed to distribute Crystawash Extend in that
country and more agreements are expected to follow.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Footnotes
1. VITRO-SKIN®; Florida Suncare Testing, Inc. IMS Division.
https://ims-usa.com/vitro-skin-
substrates/vitro-skin/
2. AFT Pharmaceuticals/AsureQuality Laboratory Services, New Zealand microbiological effectiveness
study evaluating residual killing activity against transient microbial skin flora on synthetic skin (test
organisms: S.Aureus NZRM 147/ATCC 6538 and E.Coli NZRM 2577/ATCC 8739).
3. Time Kill Test conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMD-110, EN
13727; Test organisms: S.Aureus ATCC 6538, E.Coli NCTC 10538, P.aeruginosa ATCC 15442, and E.
hirae ATCC 10541
4. Virucidal Test by Carrier Method conducted by Eurofins BioPharma Product Testing, Australia;
Protocol: TMCV 006, ASTM E1053; Test organisms: Murine hepatitis virus (MHV1) ATCC/VR-261.


For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development program forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.